FDA Investigator Nilufer M Tampal, PhD
Nilufer M Tampal, PhD has conducted inspections on 13 sites in 4 countries as of 28 Mar 2022. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
13
Last Inspection Date:
28 Mar 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America,
Canada,
France,
Germany
FDA Investigators that have inspected at least one site in common with Nilufer M Tampal, PhD:
Alan P Kurtzberg,
Allen F Hall,
Allen Lou,
Arindam Dasgupta, PhD,
Barbara J Maulfair,
Barbara Janine Breithaupt,
Barbara M Frazier,
Bill Tacket, Jr,
Bonita S Chester,
Brunilda Torres,
Carl J Montgomery,
Carla A Norris,
Carol S Sanchez,
Charles M Edwards,
Chris A Sack,
Christina N Maurino,
Christine M Whitby, CSO,
Craig A Garmendia,
Cynthia L Evitt,
Dana M Klimavicz,
Dawn L Wydner,
Deborah B Nixon,
Dr. Abhijit Raha, PhD,
Dr. Sriram Subramaniam, PhD,
Edwin Martinez,
Eric C Nielsen,
Eric M Mueller, PharmD,
Eric S Weilage,
George C Amedro,
George Ivan Wey,
Gianine E Tompkins,
Iris C Macinnes,
Jacqueline A O'shaughnessy, PhD,
James M Kewley,
James P Mcevoy,
Jane E Nelson,
Jeanne D Shaffer,
Jeffrey P Raimondi,
Jennifer A Longie Vollom,
Jessica E Hensley,
Jessica L Peterson,
John A Kadavil, PhD,
Jonathan R Campos,
Jonee J Mearns,
Joseph R Lambert,
Jyoti B Patel, PhD,
Kara A Scheibner, PhD,
Karen M Kondas,
Krystal O Ogunremi,
Larry K Austin,
Latonya M Mitchell,
LCDR Ismael Olvera, IV,
Linda R Kuchenthal,
Lisa P Oakes,
Lori A Gioia,
Lynette P Salisbury,
Margaret M Annes,
Martin K Yau, PhD,
Melkamu Getie Kebtie, PhD,
Michael F Skelly, PhD,
Mohsen Rajabi Abhari, FDA,
Muralidhara B Gavini, PhD,
Nancy A Bellamy,
Pamela L Velez Vega,
Patrick D Stone, MS,
Patrick L Wisor,
Peter R Lenahan,
Raymond T Oji,
Rebecca Rodriguez,
Richard W Berning,
Robert C Steyert,
Rodney D Combs,
Sarah Forney,
Scott B Laufenberg,
Sharon L Matson,
Shirley H Isbill,
Sripal R Mada, PhD,
Stephanie L Shapley,
Susan F Laska, MS,
Susanna E Ford,
Truong Xuan Nguyen (Andy),
Vickie J Kanion,
William L Bargo,
Xikui Chen (nmi), PhD,
Yiyue Zhang (nmi), PhD
Nilufer M Tampal, PhD's Documents
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more